Breaking News Instant updates and real-time market news.

ETTX

Entasis Therapeutics

$6.45

(0.00%)

, OXFD

Oxford Immunotec

$15.41

-0.09 (-0.58%)

08:06
04/16/19
04/16
08:06
04/16/19
08:06

Entasis Therapeutics names Elizabeth Keiley as general counsel

Entasis Therapeutics (ETTX) announced the appointment of Elizabeth Keiley as General Counsel. Keiley's primary responsibility will be to manage the company's legal activities and to lead its compliance and corporate governance functions. Prior to joining Entasis, Keiley was Senior Vice President, General Counsel at Oxford Immunotec (OXFD).

ETTX

Entasis Therapeutics

$6.45

(0.00%)

OXFD

Oxford Immunotec

$15.41

-0.09 (-0.58%)

ETTX Entasis Therapeutics
$6.45

(0.00%)

11/08/18
FBCO
11/08/18
NO CHANGE
Target $18
FBCO
Outperform
NEJM article on Entasis' Zoli increases awareness, validates novelty, says Credit Suisse
Credit Suisse analyst Martin Auster notes that Entasis Therapeutics' Phase 2 trial produced positive results, per protocol, demonstrating Zoliflodacin's potential impact on the growing antibiotic-resistance epidemic. As characterized by an NEJM editorial, N. gonorrhea can be a devastating infection if untreated, so the emergence of antibiotic-resistant strands is rather troublesome, he contends, adding that the article describes Zoli's single-dose regimen as "promising," owing to the challenges that occur when following up with patients. Auster continues to believe that an oral, single dose alternative to the SoC will add visibility and credibility to the company's novel pipeline. The analyst reiterates an Outperform rating and $18 price target on the shares.
10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/18
RHCO
10/24/18
INITIATION
Target $20
RHCO
Buy
Entasis Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Entasis Therapeutics with a Buy rating and a price target of $20, saying the company is "uniquely positioned by targeting bacterial infections where few therapeutic options exist" while also "increasing rates of multi-drug resistance". The analyst notes that Entasis' lead antibiotic "has the potential to grab significant market share as the drug will target well-defined patient populations with limited treatment options" given up to 200K of registered Acinetobacter infections in the U.S. and the E.U.
10/22/18
FBCO
10/22/18
INITIATION
Target $18
FBCO
Outperform
Entasis Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started Entasis Therapeutics with an Outperform rating and $18 price target. The analyst notes that Entasis has two Phase 3-ready assets, with ETX2514 being the key value driver for the stock. ETX2514 is being developed to address difficult-to-treat Acinetobacter infections, and has shown promising preclinical efficacy, good tissue distribution, and a clean safety profile to date, he contends. Auster is modeling a 45% probability of success to this program, but projects a potential $400M global peak opportunity by 2033 in this setting.
OXFD Oxford Immunotec
$15.41

-0.09 (-0.58%)

03/12/19
BARD
03/12/19
NO CHANGE
Target $19
BARD
Outperform
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
Baird analyst Catherine Ramsey Schulte says Oxford Immunotec reported a "solid" Q4 on Monday, with double-digit TB growth across all major geographies. In a research note to investors, the analyst says she thinks 2019 guidance seems conservative and believes double-digit TB growth should be doable, but notes that she does not expect a meaningful revenue inflection from the Quest deal until 2020 and beyond. She maintains an Outperform rating on the shares with a $19 price target.
03/12/19
PIPR
03/12/19
NO CHANGE
Target $20
PIPR
Overweight
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
Piper Jaffray analyst William Quirk says Oxford Immunotec last night reported a "solid" quarter, with pro-forma revenue above consensus, earnings in-line and guidance above consensus. With "incremental visibility" into the new business model, the analyst is confident the company is setting itself up well for a strong transition in 2019. He reiterates an Overweight rating on the shares with a $20 price target.
03/08/19
PIPR
03/08/19
NO CHANGE
Target $20
PIPR
Overweight
Oxford Immunotec $20 price target reinstated at Piper Jaffray
Piper Jaffray analyst William Quirk kept his Overweight rating and reinstated a $20 price target on Oxford Immunotec, reflecting his updated model of the company as a "largely product focused" one. The analyst also models his price target based on the 4-times multiple of his expected $79M in FY20 revenue.
11/09/18
PIPR
11/09/18
NO CHANGE
PIPR
Overweight
Oxford Immunotec price target suspended at Piper Jaffray
Piper Jaffray analyst William Quirk kept his Overweight rating on Oxford Immunotec but suspended his $14 price target after its Q3 results this morning, saying its revenues did not include the "impact of the new supplier relationship with Quest". The analyst notes that the decision further reflects his "lack of insight into future results", even though he "still expects the new Oxford model to reflect a more rapid shift to profitability."

TODAY'S FREE FLY STORIES

CRS

Carpenter Technology

$50.49

-0.22 (-0.43%)

08:05
04/25/19
04/25
08:05
04/25/19
08:05
Earnings
Carpenter Technology reports Q3 EPS $1.05 including benefit, consensus 83c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

HFWA

Heritage Financial

$31.37

0.38 (1.23%)

08:05
04/25/19
04/25
08:05
04/25/19
08:05
Earnings
Heritage Financial reports Q1 EPS 45c, consensus 49c »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

  • 01

    May

08:05
04/25/19
04/25
08:05
04/25/19
08:05
General news
U.S. durable goods preview: »

U.S. durable goods…

08:05
04/25/19
04/25
08:05
04/25/19
08:05
General news
Oil Action: WTI crude »

Oil Action: WTI crude is…

08:05
04/25/19
04/25
08:05
04/25/19
08:05
General news
U.S equities are mixed »

U.S equities are mixed in…

FCX

Freeport McMoRan

$13.57

0.115 (0.85%)

08:05
04/25/19
04/25
08:05
04/25/19
08:05
Earnings
Freeport McMoRan reports Q1 adjusted EPS 5c, consensus 8c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ITW

Illinois Tool Works

$156.78

-1.14 (-0.72%)

08:04
04/25/19
04/25
08:04
04/25/19
08:04
Earnings
Illinois Tool Works reports Q1 EPS $1.81, consensus $1.81 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

CAT

Caterpillar

$137.68

-4.4 (-3.10%)

08:04
04/25/19
04/25
08:04
04/25/19
08:04
Recommendations
Caterpillar analyst commentary  »

Caterpillar's recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

DVA

DaVita

$54.03

1.01 (1.90%)

08:03
04/25/19
04/25
08:03
04/25/19
08:03
Hot Stocks
DaVita contracts with Longroad Energy on two virtual power purchase agreements »

By 2022, DaVita expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$710.00

7.61 (1.08%)

08:03
04/25/19
04/25
08:03
04/25/19
08:03
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

FTDR

Frontdoor

$34.32

0.63 (1.87%)

08:03
04/25/19
04/25
08:03
04/25/19
08:03
Initiation
Frontdoor initiated  »

Frontdoor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 08

    May

TSLA

Tesla

$258.70

-5.15 (-1.95%)

08:02
04/25/19
04/25
08:02
04/25/19
08:02
Recommendations
Tesla analyst commentary at BofA/Merrill »

BofA says Tesla seems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PATK

Patrick Industries

$55.40

0.12 (0.22%)

08:02
04/25/19
04/25
08:02
04/25/19
08:02
Earnings
Patrick Industries reports Q1 EPS 90c, consensus 88c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

HESM

Hess Midstream Partners

$22.89

0.09 (0.39%)

08:00
04/25/19
04/25
08:00
04/25/19
08:00
Hot Stocks
Hess Midstream Partners plans to expand natural gas processing capacity »

Hess Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

HAS

Hasbro

$103.18

2.84 (2.83%)

08:00
04/25/19
04/25
08:00
04/25/19
08:00
Downgrade
Hasbro rating change  »

Hasbro downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 29

    May

08:00
04/25/19
04/25
08:00
04/25/19
08:00
General news
U.S. initial jobless claims preview: »

U.S. initial jobless…

NMCI

Navios Maritime Containers

$2.24

(0.00%)

07:58
04/25/19
04/25
07:58
04/25/19
07:58
Hot Stocks
Navios Maritime Containers announces delivery of one containership »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRCX

Lam Research

$195.40

0.56 (0.29%)

07:56
04/25/19
04/25
07:56
04/25/19
07:56
Recommendations
Lam Research analyst commentary at Citi »

Citi ups target on top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TSLA

Tesla

$258.70

-5.15 (-1.95%)

07:55
04/25/19
04/25
07:55
04/25/19
07:55
Downgrade
Tesla rating change  »

Tesla downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

07:55
04/25/19
04/25
07:55
04/25/19
07:55
Recommendations
Microsoft analyst commentary at BMO Capital »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

VBIV

VBI Vaccines

$2.00

(0.00%)

07:55
04/25/19
04/25
07:55
04/25/19
07:55
Conference/Events
VBI Vaccines to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 23

    May

UBSI

United Bankshares

$38.81

0.03 (0.08%)

07:53
04/25/19
04/25
07:53
04/25/19
07:53
Earnings
United Bankshares reports Q1 EPS 62c, consensus 61c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 15

    May

HBAN

Huntington Bancshares

$13.75

-0.04 (-0.29%)

07:53
04/25/19
04/25
07:53
04/25/19
07:53
Hot Stocks
Huntington Bancshares reaffirms three-year target of 4%-6% revenue growth »

For 2019, sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 31

    May

  • 29

    Aug

APC

Anadarko

$71.41

7.29 (11.37%)

, OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

07:52
04/25/19
04/25
07:52
04/25/19
07:52
Downgrade
Anadarko, Occidental Petroleum, Chevron rating change at Jefferies »

Jefferies downgrades…

APC

Anadarko

$71.41

7.29 (11.37%)

OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

CVX

Chevron

$118.31

-3.69 (-3.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 30

    Apr

  • 07

    May

  • 10

    May

  • 14

    May

  • 22

    May

  • 29

    May

MTSI

Macom

$15.86

-0.33 (-2.04%)

07:51
04/25/19
04/25
07:51
04/25/19
07:51
Downgrade
Macom rating change  »

Macom downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.